EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management

Samar A Antar, Nada A Ashour, Amir O Hamouda, Ayman M Noreddin, Ahmed A Al-Karmalawy

Inflammopharmacology · 2024-10 · 32 (5) · 2649-2680

DOI: 10.1007/s10787-024-01535-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 10.08.2024. Verfasst von Samar A Antar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vascular and Heart Research, Fralin Biomedical Research Institute, Virginia Tech, Roanoke, VA, 24016, USA. Hauptthemen laut MEDLINE: COVID-19, Liver Diseases, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 225 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the start of the pandemic, considerable advancements have been made in our understanding of the effects of SARS-CoV-2 infection and the associated COVID-19 on the hepatic system. There is a broad range of clinical symptoms for COVID-19. It affects multiple systems and has a dominant lung illness depending on complications. The progression of COVID-19 in people with pre-existing chronic liver disease (CLD) has also been studied in large multinational groups. Notably, SARS-CoV-2 infection is associated with a higher risk of hepatic decompensation and death in patients with cirrhosis. In this review, the source, composition, mechanisms, transmission characteristics, clinical characteristics, therapy, and prevention of SARS-CoV-2 were clarified and discussed, as well as the evolution and variations of the virus. This review briefly discusses the causes and effects of SARS-CoV-2 infection in patients with CLD. As part of COVID-19, In addition, we assess the potential of liver biochemistry as a diagnostic tool examine the data on direct viral infection of liver cells, and investigate potential pathways driving SARS-CoV-2-related liver damage. Finally, we explore how the pandemic has had a significant impact on patient behaviors and hepatology services, which may increase the prevalence and severity of liver disease in the future. The topics encompassed in this review encompass the intricate relationships between SARS-CoV-2, liver health, and broader health management strategies, providing valuable insights for both current clinical practice and future research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Liver DiseasesSARS-CoV-2HumansLiver

Stichwörter der Autor:innen

COVID-19COVID-19 managementChronic liver diseaseCirrhosisLiver injurySARS-CoV-2

Autor:innen und Institutionen

  • Center for Vascular and Heart Research, Fralin Biomedical Research Institute, Virginia Tech, Roanoke, VA, 24016, USA.
  • Department of Pharmacology, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Ahram Canadian University, 6Th of October City, Giza, 12566, Egypt.
  • Department of Internal Medicine, School of Medicine, University of California -Irvine, Irvine, USA.

Zitieren

APA

Antar, S. A., Ashour, N. A., Hamouda, A. O., Noreddin, A. M., & Al-Karmalawy, A. A. (2024). Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management. Inflammopharmacology, 32(5), 2649-2680. https://doi.org/10.1007/s10787-024-01535-7

Vancouver

Antar SA, Ashour NA, Hamouda AO, Noreddin AM, Al-Karmalawy AA. Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management. Inflammopharmacology. 2024;32(5):2649-2680. doi:10.1007/s10787-024-01535-7

BibTeX
@article{Antar2024,
  author = {Antar, Samar A and Ashour, Nada A and Hamouda, Amir O and Noreddin, Ayman M and Al-Karmalawy, Ahmed A},
  title = {Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management},
  journal = {Inflammopharmacology},
  year = {2024},
  volume = {32},
  number = {5},
  pages = {2649--2680},
  doi = {10.1007/s10787-024-01535-7}
}
Kostenlos starten →